These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38518518)

  • 1. IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital.
    Gutierrez G; Kang MJY; Vazquez G
    Psychiatry Res; 2024 May; 335():115865. PubMed ID: 38518518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
    Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
    J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
    Feifel D; Malcolm B; Boggie D; Lee K
    J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
    J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
    Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
    Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
    J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.
    Gutierrez G; Swainson J; Ravindran N; Lam RW; Giacobbe P; Karthikeyan G; Kowara A; Do A; Baskaran A; Nestor SM; Kang MJY; Biorac A; Vazquez G
    Psychiatry Res; 2024 Oct; 340():116125. PubMed ID: 39128167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.
    Sinyor M; Williams M; Belo S; Orser B; Vincent M; Mah L; Zarate C; Castel S; Levitt AJ; Schaffer A
    J Affect Disord; 2018 Dec; 241():103-109. PubMed ID: 30107350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
    DiazGranados N; Ibrahim LA; Brutsche NE; Ameli R; Henter ID; Luckenbaugh DA; Machado-Vieira R; Zarate CA
    J Clin Psychiatry; 2010 Dec; 71(12):1605-11. PubMed ID: 20673547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
    Feeney A; Hock RS; Freeman MP; Flynn M; Hoeppner B; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Fava M; Papakostas GI
    Eur Neuropsychopharmacol; 2021 Aug; 49():122-132. PubMed ID: 34090255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic and Safety Outcomes of Intravenous Ketamine for Treatment-refractory Depression in a Veteran Population: A Case Series.
    Vitek G; Langenfeld R; Walters RW; Elson A; Driscoll D; Ramaswamy S
    Mil Med; 2023 Jul; 188(7-8):e2242-e2248. PubMed ID: 36539918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?
    Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Cao B; Lee Y; Gill H; Lui LMW; Cubała WJ; Ho R; Shekotikhina M; Teopiz KM; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
    J Sleep Res; 2022 Feb; 31(1):e13400. PubMed ID: 34137095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of melancholic features on positive and negative suicidal ideation in patients with treatment-resistant depression and strong suicidal ideation receiving low-dose ketamine infusion.
    Chen MH; Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC
    Eur Arch Psychiatry Clin Neurosci; 2024 Jun; 274(4):759-766. PubMed ID: 38052767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
    McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
    Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of repeated ketamine infusions for treatment resistant depression during the COVID-19 pandemic.
    Rosenblat JD; Lipsitz O; Di Vincenzo JD; Rodrigues NB; Kratiuk K; Subramaniapillai M; Lee Y; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Wong L; Mansur RB; McIntyre RS
    Psychiatry Res; 2021 Sep; 303():114086. PubMed ID: 34246008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anhedonia and suicidal ideation in patients with treatment-refractory depression after intravenous ketamine infusions.
    Zheng W; Gu LM; Yang XH; Zhou YL; Wang CY; Lan XF; Zhang B; Ning YP
    Int J Psychiatry Clin Pract; 2023 Jun; 27(2):145-150. PubMed ID: 36309806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
    J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.